Axon Enterprise (AXON)
(Delayed Data from NSDQ)
$404.51 USD
+5.29 (1.33%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $404.53 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$404.51 USD
+5.29 (1.33%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $404.53 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) stock lucrative to the option traders.
Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.
Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session
by Zacks Equity Research
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Geron (GERN) in Focus: Stock Moves 9.2% Higher
by Zacks Equity Research
Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.
Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher
by Zacks Equity Research
Alkermes plc (ALKS) saw its shares rise over 11% on the day.
Envision Healthcare (EVHC) Looks Good: Stock Adds 10.9% in Session
by Zacks Equity Research
Envision Healthcare (EVHC) was a big mover last session, as the company saw its shares rise almost 11% on the day amid huge volumes.
Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%
by Zacks Equity Research
Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.
uniQure (QURE) in Focus: Stock Moves 11.9% Higher
by Zacks Equity Research
uniQure (QURE) saw its shares rise nearly 12% on the day.
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.
Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise over 6% on the day.
Athersys (ATHX) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.
Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Company News For Sep 27, 2017
by Zacks Equity Research
Companies in the news are: RHT,DRI,CCL,AXON
Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.
Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Axovant Sciences Ltd. (AXON) was a big mover last session, as the company saw its shares rise over 7% on the day.
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
High level of implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Axovant Sciences (AXON) needs Investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Axovant Sciences (AXON) warrants investors' attention based on moves in the options market lately.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Investors in Axovant Sciences Ltd. (AXON) need to pay close attention to the stock based on moves in the options market lately.
Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) reported loss of 9 cents per share in the first quarter of 2017, same as in the year-ago period but wider than the Zacks Consensus Estimate of a loss of 8 cents.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Axovant Sciences (AXON) warrants investors' attention based on moves in the options market lately.